pilocarpine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| tricyclic compounds | 2166 | 92-13-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | mg | O |
| 10 | mg | P |
| 0.40 | ml | None |
| 40 | mg | ointment |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| fu (Fraction unbound in plasma) | 0.92 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 29, 1974 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Limb injury | 54.49 | 16.48 | 35 | 7341 | 25442 | 63456204 |
| Vitreous detachment | 51.75 | 16.48 | 16 | 7360 | 2011 | 63479635 |
| Occult blood | 49.56 | 16.48 | 14 | 7362 | 1287 | 63480359 |
| Angioplasty | 48.63 | 16.48 | 14 | 7362 | 1378 | 63480268 |
| Glaucoma | 42.98 | 16.48 | 27 | 7349 | 18878 | 63462768 |
| Vitreous floaters | 41.34 | 16.48 | 18 | 7358 | 5948 | 63475698 |
| Choking | 41.22 | 16.48 | 21 | 7355 | 9858 | 63471788 |
| Eye pain | 41.18 | 16.48 | 33 | 7343 | 33821 | 63447825 |
| Peripheral vascular disorder | 41.14 | 16.48 | 18 | 7358 | 6017 | 63475629 |
| Vitreoretinal traction syndrome | 38.71 | 16.48 | 6 | 7370 | 24 | 63481622 |
| Vision blurred | 37.97 | 16.48 | 50 | 7326 | 91874 | 63389772 |
| Dry eye | 37.82 | 16.48 | 34 | 7342 | 40727 | 63440919 |
| Visual impairment | 34.98 | 16.48 | 46 | 7330 | 84400 | 63397246 |
| Eye irritation | 34.63 | 16.48 | 25 | 7351 | 21946 | 63459700 |
| Transient ischaemic attack | 34.06 | 16.48 | 31 | 7345 | 37722 | 63443924 |
| Crepitations | 33.28 | 16.48 | 17 | 7359 | 8023 | 63473623 |
| Acute myocardial infarction | 28.24 | 16.48 | 26 | 7350 | 32098 | 63449548 |
| Spinal osteoarthritis | 26.85 | 16.48 | 19 | 7357 | 16167 | 63465479 |
| Iritis | 26.72 | 16.48 | 11 | 7365 | 3164 | 63478482 |
| Sputum discoloured | 26.68 | 16.48 | 19 | 7357 | 16328 | 63465318 |
| Iron deficiency | 26.24 | 16.48 | 14 | 7362 | 7216 | 63474430 |
| Hot flush | 26.19 | 16.48 | 31 | 7345 | 51128 | 63430518 |
| Coronary artery disease | 26.14 | 16.48 | 25 | 7351 | 32352 | 63449294 |
| Tanning | 25.86 | 16.48 | 5 | 7371 | 85 | 63481561 |
| Haemorrhage | 24.89 | 16.48 | 33 | 7343 | 60989 | 63420657 |
| Urinary retention | 23.72 | 16.48 | 23 | 7353 | 30278 | 63451368 |
| Accommodation disorder | 23.50 | 16.48 | 6 | 7370 | 375 | 63481271 |
| Body temperature fluctuation | 22.98 | 16.48 | 9 | 7367 | 2276 | 63479370 |
| Conjunctival hyperaemia | 22.63 | 16.48 | 9 | 7367 | 2370 | 63479276 |
| Pulmonary congestion | 21.22 | 16.48 | 17 | 7359 | 17401 | 63464245 |
| Cardiac failure congestive | 20.81 | 16.48 | 38 | 7338 | 92395 | 63389251 |
| Blood pressure systolic decreased | 20.51 | 16.48 | 12 | 7364 | 7385 | 63474261 |
| Intraocular pressure increased | 19.92 | 16.48 | 11 | 7365 | 6067 | 63475579 |
| Blood pressure diastolic increased | 19.55 | 16.48 | 13 | 7363 | 9997 | 63471649 |
| Corneal oedema | 19.06 | 16.48 | 7 | 7369 | 1486 | 63480160 |
| Toxicity to various agents | 18.99 | 16.48 | 3 | 7373 | 247247 | 63234399 |
| Dry mouth | 18.79 | 16.48 | 33 | 7343 | 77830 | 63403816 |
| Asthma | 18.76 | 16.48 | 44 | 7332 | 127517 | 63354129 |
| Myocardial infarction | 18.73 | 16.48 | 38 | 7338 | 99855 | 63381791 |
| Blood pressure increased | 17.73 | 16.48 | 50 | 7326 | 162012 | 63319634 |
| Open fracture | 17.72 | 16.48 | 5 | 7371 | 458 | 63481188 |
| Ocular hyperaemia | 17.67 | 16.48 | 18 | 7358 | 25126 | 63456520 |
| Epstein-Barr virus associated lymphoma | 17.16 | 16.48 | 5 | 7371 | 513 | 63481133 |
| Photopsia | 17.12 | 16.48 | 9 | 7367 | 4500 | 63477146 |
| Pulmonary oedema | 16.95 | 16.48 | 26 | 7350 | 54847 | 63426799 |
| Platelet count increased | 16.87 | 16.48 | 15 | 7361 | 17696 | 63463950 |
| Productive cough | 16.85 | 16.48 | 28 | 7348 | 63180 | 63418466 |
| Increased tendency to bruise | 16.61 | 16.48 | 12 | 7364 | 10540 | 63471106 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Vitreous detachment | 91.46 | 28.81 | 17 | 1128 | 871 | 34954915 |
| Visual impairment | 88.98 | 28.81 | 36 | 1109 | 35766 | 34920020 |
| Retinal tear | 72.51 | 28.81 | 14 | 1131 | 879 | 34954907 |
| Retinal detachment | 70.22 | 28.81 | 19 | 1126 | 5372 | 34950414 |
| Vitreous floaters | 62.86 | 28.81 | 16 | 1129 | 3569 | 34952217 |
| Intraocular pressure increased | 60.97 | 28.81 | 17 | 1128 | 5366 | 34950420 |
| Vision blurred | 41.42 | 28.81 | 23 | 1122 | 45940 | 34909846 |
| Photopsia | 40.55 | 28.81 | 10 | 1135 | 1958 | 34953828 |
| Treatment failure | 35.71 | 28.81 | 21 | 1124 | 46676 | 34909110 |
| Ocular hyperaemia | 33.54 | 28.81 | 13 | 1132 | 11439 | 34944347 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Limb injury | 65.36 | 17.20 | 37 | 6701 | 29491 | 79708159 |
| Glaucoma | 55.51 | 17.20 | 29 | 6709 | 19732 | 79717918 |
| Angioplasty | 53.53 | 17.20 | 15 | 6723 | 1848 | 79735802 |
| Occult blood | 50.09 | 17.20 | 14 | 6724 | 1709 | 79735941 |
| Intraocular pressure increased | 49.02 | 17.20 | 21 | 6717 | 9184 | 79728466 |
| Choking | 46.57 | 17.20 | 22 | 6716 | 12079 | 79725571 |
| Vitreous detachment | 46.34 | 17.20 | 14 | 6724 | 2245 | 79735405 |
| Vitreous floaters | 43.47 | 17.20 | 18 | 6720 | 7238 | 79730412 |
| Peripheral vascular disorder | 41.71 | 17.20 | 18 | 6720 | 8012 | 79729638 |
| Transient ischaemic attack | 39.64 | 17.20 | 34 | 6704 | 52661 | 79684989 |
| Crepitations | 37.90 | 17.20 | 18 | 6720 | 9999 | 79727651 |
| Sputum discoloured | 29.61 | 17.20 | 20 | 6718 | 21723 | 79715927 |
| Hot flush | 28.85 | 17.20 | 29 | 6709 | 54848 | 79682802 |
| Dry eye | 28.11 | 17.20 | 24 | 6714 | 36907 | 79700743 |
| Tanning | 27.56 | 17.20 | 5 | 6733 | 83 | 79737567 |
| Haemorrhage | 27.29 | 17.20 | 36 | 6702 | 91082 | 79646568 |
| Visual impairment | 26.97 | 17.20 | 36 | 6702 | 92095 | 79645555 |
| Urinary retention | 26.29 | 17.20 | 28 | 6710 | 56602 | 79681048 |
| Vitreoretinal traction syndrome | 25.88 | 17.20 | 4 | 6734 | 23 | 79737627 |
| Iron deficiency | 25.33 | 17.20 | 14 | 6724 | 10640 | 79727010 |
| Wound | 24.68 | 17.20 | 39 | 6699 | 116140 | 79621510 |
| Iritis | 24.58 | 17.20 | 10 | 6728 | 3845 | 79733805 |
| Vision blurred | 24.53 | 17.20 | 37 | 6701 | 105861 | 79631789 |
| Cardiac failure congestive | 23.87 | 17.20 | 43 | 6695 | 142359 | 79595291 |
| Conjunctival hyperaemia | 23.27 | 17.20 | 10 | 6728 | 4403 | 79733247 |
| Asthma | 22.91 | 17.20 | 41 | 6697 | 135054 | 79602596 |
| Weight increased | 22.85 | 17.20 | 63 | 6675 | 277323 | 79460327 |
| Eye pain | 21.87 | 17.20 | 21 | 6717 | 37557 | 79700093 |
| Spinal osteoarthritis | 21.70 | 17.20 | 15 | 6723 | 16912 | 79720738 |
| Pulmonary congestion | 21.42 | 17.20 | 18 | 6720 | 27082 | 79710568 |
| Body temperature fluctuation | 21.31 | 17.20 | 9 | 6729 | 3798 | 79733852 |
| Ocular surface disease | 19.82 | 17.20 | 4 | 6734 | 119 | 79737531 |
| Coronary artery disease | 19.80 | 17.20 | 26 | 6712 | 65448 | 79672202 |
| Acne | 19.34 | 17.20 | 17 | 6721 | 27173 | 79710477 |
| Blood pressure diastolic increased | 18.91 | 17.20 | 13 | 6725 | 14529 | 79723121 |
| Open fracture | 18.86 | 17.20 | 5 | 6733 | 500 | 79737150 |
| Exposure to communicable disease | 18.49 | 17.20 | 5 | 6733 | 539 | 79737111 |
| Accommodation disorder | 18.03 | 17.20 | 5 | 6733 | 593 | 79737057 |
| Corneal oedema | 17.40 | 17.20 | 7 | 6731 | 2613 | 79735037 |
| Blood pressure increased | 17.38 | 17.20 | 48 | 6690 | 211312 | 79526338 |
| Toxicity to various agents | 17.29 | 17.20 | 7 | 6731 | 421533 | 79316117 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07AX01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Other parasympathomimetics |
| ATC | S01EB01 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| ATC | S01EB51 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| FDA MoA | N0000000104 | Cholinergic Muscarinic Agonists |
| FDA MoA | N0000175369 | Cholinergic Agonists |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| MeSH PA | D008916 | Miotics |
| MeSH PA | D018721 | Muscarinic Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| CHEBI has role | CHEBI:39456 | antiglaucoma agent |
| FDA EPC | N0000175884 | Cholinergic Receptor Agonist |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ocular hypertension | indication | 4210003 | DOID:9282 |
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
| Aptyalism | indication | 87715008 | |
| Xerostomia Secondary to Sjogren's Syndrome | indication | ||
| Primary Closed Angle Glaucoma | indication | ||
| Xerostomia Secondary to Radiation Therapy | indication | ||
| Bronchospasm | contraindication | 4386001 | |
| Keratitis | contraindication | 5888003 | DOID:4677 |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Retinal detachment | contraindication | 42059000 | DOID:5327 |
| Hepatic failure | contraindication | 59927004 | |
| Iritis | contraindication | 65074000 | DOID:1406 |
| Cholecystitis | contraindication | 76581006 | DOID:1949 |
| Kidney stone | contraindication | 95570007 | |
| Disorder of biliary tract | contraindication | 105997008 | DOID:9741 |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Calculus in biliary tract | contraindication | 266474003 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Anterior uveitis | contraindication | 410692006 | DOID:1407 |
| Acute exacerbation of asthma | contraindication | 708038006 | |
| Psychiatric Disturbance | contraindication | ||
| Pupillary Block Glaucoma | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.04 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | 10610518 | April 24, 2039 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY |
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | 10610518 | April 24, 2039 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY |
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | 10610518 | April 24, 2039 | USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS |
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | 11285134 | April 24, 2039 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY |
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | 11285134 | April 24, 2039 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY |
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | 11285134 | April 24, 2039 | USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | Oct. 28, 2024 | NEW PRODUCT |
| 1.25% | VUITY | ABBVIE | N214028 | Oct. 28, 2021 | RX | SOLUTION | OPHTHALMIC | March 28, 2026 | ADDITION OF SECOND DOSE FOR TREATMENT OF PRESBYOPIA IN ADULTS |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | EC50 | 6.97 | SCIENTIFIC LITERATURE | IUPHAR | |||
| Muscarinic acetylcholine receptor M1 | GPCR | AGONIST | EC50 | 7.02 | SCIENTIFIC LITERATURE | ||||
| Muscarinic acetylcholine receptor M2 | GPCR | AGONIST | EC50 | 6.95 | SCIENTIFIC LITERATURE | ||||
| Muscarinic acetylcholine receptor M4 | GPCR | AGONIST | EC50 | 7.15 | SCIENTIFIC LITERATURE | ||||
| Muscarinic acetylcholine receptor M5 | GPCR | AGONIST | EC50 | 7 | SCIENTIFIC LITERATURE | ||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.51 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | EC50 | 5.16 | CHEMBL | |||||
| Muscarinic acetylcholine receptor DM1 | GPCR | Ki | 5.55 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Ki | 7.08 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.01 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00525 | KEGG_DRUG |
| 148-72-1 | SECONDARY_CAS_RN |
| 54-71-7 | SECONDARY_CAS_RN |
| 4018207 | VANDF |
| 4018208 | VANDF |
| 4018209 | VANDF |
| 4020904 | VANDF |
| C0031923 | UMLSCUI |
| CHEBI:8207 | CHEBI |
| 9PL | PDB_CHEM_ID |
| CHEMBL550 | ChEMBL_ID |
| CHEMBL611494 | ChEMBL_ID |
| DB01085 | DRUGBANK_ID |
| CHEMBL1200330 | ChEMBL_ID |
| CHEMBL1213136 | ChEMBL_ID |
| D010862 | MESH_DESCRIPTOR_UI |
| 5910 | PUBCHEM_CID |
| 305 | IUPHAR_LIGAND_ID |
| 01MI4Q9DI3 | UNII |
| 103244 | RXNORM |
| 1396 | MMSL |
| 20709 | MMSL |
| 3317 | MMSL |
| 44345 | MMSL |
| 5299 | MMSL |
| 5300 | MMSL |
| 72427 | MMSL |
| 73122 | MMSL |
| d04031 | MMSL |
| 001693 | NDDF |
| 001694 | NDDF |
| 001695 | NDDF |
| 372895002 | SNOMEDCT_US |
| 387035001 | SNOMEDCT_US |
| 395827004 | SNOMEDCT_US |
| 90356005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VUITY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0074-7098 | SOLUTION/ DROPS | 12.50 mg | OPHTHALMIC | NDA | 26 sections |
| VUITY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0074-7098 | SOLUTION/ DROPS | 12.50 mg | OPHTHALMIC | NDA | 26 sections |
| VUITY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0074-7098 | SOLUTION/ DROPS | 12.50 mg | OPHTHALMIC | NDA | 26 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-5911 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 23 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-5922 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 23 sections |
| Pilocarpine hydrochloride | Human Prescription Drug Label | 1 | 0228-2801 | TABLET, FILM COATED | 5 mg | ORAL | NDA AUTHORIZED GENERIC | 21 sections |
| Pilocarpine hydrochloride | Human Prescription Drug Label | 1 | 0228-2837 | TABLET, FILM COATED | 7.50 mg | ORAL | NDA AUTHORIZED GENERIC | 21 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1313 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1313 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1407 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1407 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 24 sections |
| pilocarpine hydrchloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0792 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 20 sections |
| ISOPTO CARPINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0998-0203 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | NDA | 24 sections |
| ISOPTO CARPINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0998-0204 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | NDA | 24 sections |
| ISOPTO CARPINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0998-0206 | SOLUTION/ DROPS | 40 mg | OPHTHALMIC | NDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-589 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 22 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-590 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 22 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-680 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 23 sections |
| Pilocarpine Hydrochloride | Human Prescription Drug Label | 1 | 16714-121 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 20 sections |
| Pilocarpine Hydrochloride | Human Prescription Drug Label | 1 | 16714-121 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 20 sections |
| Pilocarpine Hydrochloride | Human Prescription Drug Label | 1 | 16714-122 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 20 sections |
| Pilocarpine Hydrochloride | Human Prescription Drug Label | 1 | 16714-122 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 20 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-223 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-223 | SOLUTION/ DROPS | 10 mg | OPHTHALMIC | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-224 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-224 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-226 | SOLUTION/ DROPS | 40 mg | OPHTHALMIC | ANDA | 24 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-226 | SOLUTION/ DROPS | 40 mg | OPHTHALMIC | ANDA | 24 sections |
| PILOCARPINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-368 | SOLUTION/ DROPS | 10 mg | CONJUNCTIVAL | NDA | 14 sections |
| Pilocarpine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-601 | TABLET | 5 mg | ORAL | ANDA | 23 sections |